<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39250622</PMID><DateCompleted><Year>2024</Year><Month>09</Month><Day>09</Day></DateCompleted><DateRevised><Year>2024</Year><Month>09</Month><Day>09</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1998-3751</ISSN><JournalIssue CitedMedium="Internet"><Volume>56</Volume><Issue>4</Issue><PubDate><Year>2024</Year><Month>Jul</Month><Day>01</Day></PubDate></JournalIssue><Title>Indian journal of pharmacology</Title><ISOAbbreviation>Indian J Pharmacol</ISOAbbreviation></Journal><ArticleTitle>A novel ultra-performance liquid chromatography detection method development and validation for paclitaxel and its major metabolite in human plasma.</ArticleTitle><Pagination><StartPage>253</StartPage><EndPage>259</EndPage><MedlinePgn>253-259</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.4103/ijp.ijp_557_23</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Paclitaxel is a promising anticancer drug for patients with ovarian, breast, lung, gastrointestinal, genitourinary, prostate, and head-and-neck cancers. Paclitaxel follows nonlinear pharmacokinetics. The major metabolite of paclitaxel is 6-alpha-hydroxy paclitaxel, mediated by CYP2C8, while metabolism to two of its minor metabolites, 3'-p-hydroxypaclitaxel and 6a, 3'- p-dihydroxypaclitaxel, is catalyzed by CYP3A4. Therapeutic drug monitoring of paclitaxel could be a promising approach to improve the efficacy and safety of paclitaxel correct personalized doses and improve the overall benefit-risk ratio. A novel and highly sensitive chromatographic method for the detection of paclitaxel and its metabolite has been proposed that allows quantification in human plasma with 100% accuracy in terms of recovery without significant intraday or interday variations.</AbstractText><AbstractText Label="MATERIALS AND METHODS" NlmCategory="METHODS">The present study was planned following bioanalytical method validation guidance according to the U.S. Food and Drug Administration requirements. The validation of the analytical procedure was performed as per ICH Q2(R1) guidelines. It was done to assure the reliability of the results obtained for various parameters such as linearity, accuracy, precision, limit of detection (LOD), limit of quantification, robustness, stability, and system suitability.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The specificity of the method was established by ensuring no interference with peak obtained from paclitaxel and 6-alpha-hydroxy paclitaxel. LOD was found to be 0.05 and 0.033 while the limit of quantitation was 0.14 and 0.099 for paclitaxel and 6-alpha-hydroxy paclitaxel, respectively. Median (±interquartile range) accuracy for paclitaxel and 6-alpha-hydroxy paclitaxel was found to be 102.73 (±13.581) and 100.87 (±7.573), respectively.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">This novel method of simultaneous detection of paclitaxel and its major metabolite 6-alpha-hydroxy paclitaxel demonstrated significant resolution and was sensitive enough for its quantification in human plasma.</AbstractText><CopyrightInformation>Copyright © 2024 Copyright: © 2024 Indian Journal of Pharmacology.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kumar</LastName><ForeName>Vikas</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Department of Pharmacology, All India Institute of Medical Sciences, Bathinda, Punjab, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vardhan</LastName><ForeName>Gyan</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Pharmacology, All India Institute of Medical Sciences, Bathinda, Punjab, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sehrawat</LastName><ForeName>Amit</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Medical Oncology Haematology, All India Institute of Medical Sciences, Rishikesh, Uttarakhand, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Handu</LastName><ForeName>Shailendra</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Pharmacology, All India Institute of Medical Sciences, Rishikesh, Uttarakhand, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dhamija</LastName><ForeName>Puneet</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Pharmacology, All India Institute of Medical Sciences, Rishikesh, Uttarakhand, India.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D023361">Validation Study</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>10</Day></ArticleDate></Article><MedlineJournalInfo><Country>India</Country><MedlineTA>Indian J Pharmacol</MedlineTA><NlmUniqueID>7902477</NlmUniqueID><ISSNLinking>0253-7613</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>P88XT4IS4D</RegistryNumber><NameOfSubstance UI="D017239">Paclitaxel</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000972">Antineoplastic Agents, Phytogenic</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D017239" MajorTopicYN="Y">Paclitaxel</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName><QualifierName UI="Q000031" MajorTopicYN="N">analogs &amp; derivatives</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002851" MajorTopicYN="N">Chromatography, High Pressure Liquid</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057230" MajorTopicYN="Y">Limit of Detection</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015203" MajorTopicYN="N">Reproducibility of Results</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000972" MajorTopicYN="Y">Antineoplastic Agents, Phytogenic</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016903" MajorTopicYN="N">Drug Monitoring</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>8</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>8</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>9</Month><Day>9</Day><Hour>18</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>9</Day><Hour>18</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>9</Day><Hour>14</Hour><Minute>43</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39250622</ArticleId><ArticleId IdType="doi">10.4103/ijp.ijp_557_23</ArticleId><ArticleId IdType="pii">01363791-202407000-00004</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Wellstein A, Giaccone G, Atkins MB, Sausville EA. Cytotoxic drugs Brunton LL, Knollmann BC, Hilal-Dandan R. Goodman &amp; Gilman’s: The Pharmacological Basis of Therapeutics. 13th ed., Ch. 66. New York, N.Y: McGraw-Hill Education LLC.; 2018. 1187–8.</Citation></Reference><Reference><Citation>Akhmanova A, Steinmetz MO. Control of microtubule organization and dynamics: Two ends in the limelight. Nat Rev Mol Cell Biol 2015;16:711–26.</Citation></Reference><Reference><Citation>Stage TB, Bergmann TK, Kroetz DL. Clinical pharmacokinetics of paclitaxel monotherapy:An updated literature review. Clin Pharmacokinet 2018;57:7–19.</Citation></Reference><Reference><Citation>Sonnichsen DS, Liu Q, Schuetz EG, Schuetz JD, Pappo A, Relling MV. Variability in human cytochrome P450 paclitaxel metabolism. J Pharmacol Exp Ther 1995;275:566–75.</Citation></Reference><Reference><Citation>Siddiqui N, Boddy AV, Thomas HD, Bailey NP, Robson L, Lind MJ, et al. Aclinical and pharmacokinetic study of the combination of carboplatin and paclitaxel for epithelial ovarian cancer. Br J Cancer 1997;75:287–94.</Citation></Reference><Reference><Citation>Zhang W, Dutschman GE, Li X, Cheng YC. Quantitation of paclitaxel and its two major metabolites using a liquid chromatography-electrospray ionization tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2011;879:2018–22.</Citation></Reference><Reference><Citation>Parise RA, Ramanathan RK, Zamboni WC, Egorin MJ. Sensitive liquid chromatography-mass spectrometry assay for quantitation of docetaxel and paclitaxel in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci 2003;783:231–6.</Citation></Reference><Reference><Citation>Vasantha J, Kannan G, Goud T, Palani T, Vanitha R, Anitha R, et al. Pharmacokinetic evaluation of paclitaxel in South Indian cancer patients:A prospective study. J Young Pharm 2011;3:322–8.</Citation></Reference><Reference><Citation>Gianni L, Kearns CM, Giani A, Capri G, Viganó L, Lacatelli A, et al. Nonlinear pharmacokinetics and metabolism of paclitaxel and its pharmacokinetic/pharmacodynamic relationships in humans. J Clin Oncol 1995;13:180–90.</Citation></Reference><Reference><Citation>Nakajima M, Fujiki Y, Kyo S, Kanaya T, Nakamura M, Maida Y, et al. Pharmacokinetics of paclitaxel in ovarian cancer patients and genetic polymorphisms of CYP2C8, CYP3A4, and MDR1. J Clin Pharmacol 2005;45:674–82.</Citation></Reference><Reference><Citation>Research C for DE and. Bioanalytical Method Validation Guidance for Industry. U.S. Food and Drug Administration; 2019. Available from: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/bioanalytical-method-validation-guidance-industry. [Last accessed on 2019 Nov 05].</Citation></Reference><Reference><Citation>ICH Official Web Site: ICH. Available from: https://www.ich.org/page/quality-guidelines. [Last accessed on 2019 Oct 18].</Citation></Reference><Reference><Citation>Government of India, Ministry of Health &amp; Family Welfare, The Indian Pharmacopoeia Commission. Indian Pharmacopoeia Laboratory. 8th ed. Ghaziabad: The Indian Pharmacopoeia Commission; 2018. 2843–5.</Citation></Reference><Reference><Citation>Bernabeu E, Flor S, Hocht C, Taira C, Chiappetta D, Tripodi V, et al. Development and validation of a highly sensitive HPLC method for determination of paclitaxel in pharmaceutical dosage forms and biological samples. Curr Pharm Anal 2014;10:185–92.</Citation></Reference><Reference><Citation>Zhang SQ, Chen GH. Determination of paclitaxel in human plasma by UPLC-MS-MS. J Chromatogr Sci 2008;46:220–4.</Citation></Reference><Reference><Citation>Huizing MT, Sparreboom A, Rosing H, van Tellingen O, Pinedo HM, Beijnen JH. Quantification of paclitaxel metabolites in human plasma by high-performance liquid chromatography. J Chromatogr B Biomed Appl 1995;674:261–8.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle>